
GLP-1 drugs are rewriting the restaurant playbook

Weight-loss drugs are changing what people in the West order, how much they eat, and where the restaurant sector's next margin dollar comes from - and the industry is only starting to figure out what that means for the business model. A new McKinsey roundtable on the future of restaurants dropped this month, featuring five partners across the consultancy's global network in a wide-ranging discussion covering robotics, AI-powered personalisation and the "unbundling" of the traditional dining format. But the sharpest near-term signal concerns something that isn't tech at all: GLP-1 meds. By 2025, 12% of all Americans had used some form of GLP-1 drug for weight loss, and the U.S. obesity rate fell for the first time in a decade. J.P. Morgan estimates more than 30 million Americans could be on GLP-1 treatment by 2030, up from around 10 million in 2026, and Circana projects that households with GLP-1 users will account for 35% of all U.S. food and beverage units sold by that date. The National Restaurant Association pegs the U.S. restaurant market at US$1.5 trillion, so those adoption numbers are not rounding errors.What the drugs do to diningThe McKinsey panel tackled the GLP-1 question head-on, and the takeaway was mor







